Pharmacological researches identified some molecules that seems to bring promising results to slow down diabetic retinopathy; these molecures are part of the (ACE) inhibitors and angiotensin II class, used over the years to fight hypertension.

These medications have the advantage of being delivered in a systemic way, in some cases even orally.
Anyway, he most important news come from clinical studies about anti-VEGF (Vascular Endothelial Growth Factor) medications; there can inhibit the neovascularisation and lower vascular permeability.

Sodium pegaptanib and ranibizumab, already authorized for neovascular DMLE treatment, are used “off label” (that is, not taking into account indications written in their technical files) to treat diabetica retinopathy.

Anti-VEGF drugs have to be injected directly inside the ocular bulb (intravitreal injection). This delivery method requires total sterility and great attention from the ophthalmologist.

Sodium pegaptanib and ranibizumab, already authorized for neovascular DMLE treatment, are used “off label” (that is, not taking into account indications written in their technical files) to treat diabetica retinopathy.

Furthermore intravitreal therapy anti-VEGF usually has to be repeated over time.